Anticoagulation Management With Coumarinic Drugs in Chilean Patients
Author
dc.contributor.author
Nieto, Elena
Author
dc.contributor.author
Suarez, Marcelo
Author
dc.contributor.author
Roco, Ángela
Author
dc.contributor.author
Rubilar, Juan Carlos
Author
dc.contributor.author
Tamayo, Francisca
Author
dc.contributor.author
Rojo, Mario
Author
dc.contributor.author
Verón, Gabriel
Author
dc.contributor.author
Sepúlveda, Juliana
Author
dc.contributor.author
Mejías, Fanny
Author
dc.contributor.author
Salas, Patricio
Author
dc.contributor.author
Góngora, María
Author
dc.contributor.author
Andrade, Patricio
Author
dc.contributor.author
Canales, Alicia
Author
dc.contributor.author
Carabantes, Jorge
Author
dc.contributor.author
Cruz, Daniela
Author
dc.contributor.author
Contreras, Emma
Admission date
dc.date.accessioned
2019-10-22T03:13:44Z
Available date
dc.date.available
2019-10-22T03:13:44Z
Publication date
dc.date.issued
2019
Cita de ítem
dc.identifier.citation
Clinical and Applied Thrombosis/Hemostasis, Volumen 25,
Identifier
dc.identifier.issn
19382723
Identifier
dc.identifier.issn
10760296
Identifier
dc.identifier.other
10.1177/1076029619834342
Identifier
dc.identifier.uri
https://repositorio.uchile.cl/handle/2250/171967
Abstract
dc.description.abstract
Warfarin and acenocoumarol are used in various cardiovascular disorders to improve the prognosis of patients with thromboembolic disease. However, there is a lack of substantial efficacy and safety data on antithrombotic prophylaxis in several countries, particularly in Latin America. The aim of this study was to provide information about the efficacy of anticoagulants in Chilean patients. Data were collected from databases of the Western Metropolitan Health Service, Santiago, Chile. We identified 6280 records of patients receiving anticoagulant treatment. The three most common diagnoses were rhythm disorder (43.7%), venous thrombosis (22%), and valvular prosthesis (10.7%). The majority of patients (98.5%) received acenocoumarol while 1.5% of patients received warfarin, at weekly therapeutic doses of 13.6 mg and 30.4 mg, respectively. For total diagnoses, the median time in the therapeutic range was 50%. However, better results, 66.7%, were observed when a telemedicine strategy was used only in Santiago Province. Our findings emphasize that in Chile, where the number of patients receiving anticoagulant treatment increases every year, telemedicine, by committed teams, improves the use of oral anticoagulants and is able to increase quality indicators of anticoagulant treatment care.